IL172457A - Fused compounds containing an ureido group that inhibit vanilloid receptor subtype 1 (vr1) receptor for treating disorders caused by vanilloid receptor activity and process for their preparation - Google Patents

Fused compounds containing an ureido group that inhibit vanilloid receptor subtype 1 (vr1) receptor for treating disorders caused by vanilloid receptor activity and process for their preparation

Info

Publication number
IL172457A
IL172457A IL172457A IL17245705A IL172457A IL 172457 A IL172457 A IL 172457A IL 172457 A IL172457 A IL 172457A IL 17245705 A IL17245705 A IL 17245705A IL 172457 A IL172457 A IL 172457A
Authority
IL
Israel
Prior art keywords
compound
formula
inden
dihydro
indazol
Prior art date
Application number
IL172457A
Other languages
English (en)
Other versions
IL172457A0 (en
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL172457(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/459,925 external-priority patent/US7015233B2/en
Priority claimed from US10/864,068 external-priority patent/US7375126B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL172457A0 publication Critical patent/IL172457A0/en
Publication of IL172457A publication Critical patent/IL172457A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL172457A 2003-06-12 2005-12-08 Fused compounds containing an ureido group that inhibit vanilloid receptor subtype 1 (vr1) receptor for treating disorders caused by vanilloid receptor activity and process for their preparation IL172457A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/459,925 US7015233B2 (en) 2003-06-12 2003-06-12 Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US10/864,068 US7375126B2 (en) 2003-06-12 2004-06-09 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
PCT/US2004/018590 WO2004111009A1 (en) 2003-06-12 2004-06-10 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Publications (2)

Publication Number Publication Date
IL172457A0 IL172457A0 (en) 2006-04-10
IL172457A true IL172457A (en) 2011-12-29

Family

ID=33555102

Family Applications (4)

Application Number Title Priority Date Filing Date
IL172457A IL172457A (en) 2003-06-12 2005-12-08 Fused compounds containing an ureido group that inhibit vanilloid receptor subtype 1 (vr1) receptor for treating disorders caused by vanilloid receptor activity and process for their preparation
IL207335A IL207335A (en) 2003-06-12 2010-08-01 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
IL215997A IL215997A0 (en) 2003-06-12 2011-10-27 Fused compounds containing an ureido group that inhibit vanilloid receptor subtype 1 (vr1) receptor ,for treating disorders caused by vanilloid receptor activity and process for their preparation
IL216046A IL216046A0 (en) 2003-06-12 2011-10-30 Fused compounds containing an ureido group that inhibit vanilloid receptor subtype 1 (vr1) receptor ,for treating disorders caused by vanilloid receptor activity and process for their preparation

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL207335A IL207335A (en) 2003-06-12 2010-08-01 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
IL215997A IL215997A0 (en) 2003-06-12 2011-10-27 Fused compounds containing an ureido group that inhibit vanilloid receptor subtype 1 (vr1) receptor ,for treating disorders caused by vanilloid receptor activity and process for their preparation
IL216046A IL216046A0 (en) 2003-06-12 2011-10-30 Fused compounds containing an ureido group that inhibit vanilloid receptor subtype 1 (vr1) receptor ,for treating disorders caused by vanilloid receptor activity and process for their preparation

Country Status (20)

Country Link
EP (2) EP1658269B1 (enExample)
JP (2) JP4857113B2 (enExample)
KR (2) KR101138216B1 (enExample)
CN (1) CN102617464A (enExample)
AT (2) ATE510824T1 (enExample)
AU (2) AU2004247721C1 (enExample)
BR (1) BRPI0411116A (enExample)
CA (2) CA2526872C (enExample)
CY (2) CY1108713T1 (enExample)
DE (1) DE602004017329D1 (enExample)
DK (2) DK1658269T3 (enExample)
ES (1) ES2318308T3 (enExample)
IL (4) IL172457A (enExample)
MX (1) MXPA05013550A (enExample)
NZ (3) NZ590234A (enExample)
PL (2) PL2017265T3 (enExample)
PT (2) PT1658269E (enExample)
SI (2) SI2017265T1 (enExample)
TW (3) TW201300361A (enExample)
WO (1) WO2004111009A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US20090018092A1 (en) 2004-03-16 2009-01-15 The Regents Of The University Of California Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids
AU2005295167B2 (en) 2004-10-20 2012-05-10 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
WO2006062982A2 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
JP2008523072A (ja) 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ, インコーポレイテッド タンパク質キナーゼの阻害剤
CA2624307C (en) 2005-10-07 2014-04-29 Glenmark Pharmaceuticals S.A. Substituted benzofused derivatives and their use as vanilloid receptor ligands
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
AU2006306146A1 (en) 2005-10-28 2007-05-03 Abbott Laboratories Indazole derivatives that inhibit TRPV1 receptor
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
RU2450006C2 (ru) * 2006-04-18 2012-05-10 Эбботт Лэборетриз Антагонисты ванилоидного рецептора подтипа 1(vr1) и их применение
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
CN101925575B (zh) 2008-01-28 2014-06-18 株式会社爱茉莉太平洋 作为香草酸受体拮抗剂的化合物、其异构体或其药物学可接受的盐、及包含这些化合物的药物组合物
CN102137851B (zh) 2008-07-02 2014-08-27 株式会社爱茉莉太平洋 作为香草素受体拮抗剂的化合物、其异构体或其药学可接受的盐以及包含它们的药物组合物
AR073631A1 (es) * 2008-10-17 2010-11-17 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 ( trpv1) utiles para tratar inflamacion y dolor
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
HRP20161786T1 (hr) 2011-05-13 2017-03-10 Array Biopharma, Inc. Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze
CN104364236B (zh) * 2012-05-09 2018-01-16 拜尔农作物科学股份公司 5‑卤代吡唑二氢茚基甲酰胺
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
UA117573C2 (uk) 2012-11-13 2018-08-27 Ерей Біофарма Інк. Біциклічні сполуки сечовини, тіосечовини, гуанідину й ціаногуанідину, придатні для лікування болю
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
UA116455C2 (uk) 2012-11-13 2018-03-26 Еррей Біофарма Інк. Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CN109970614B (zh) 2014-05-15 2023-01-13 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途
WO2017190107A1 (en) * 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW536734B (en) * 2000-07-31 2003-06-11 Clariant Int Ltd Process for manufacturing a microelectronic device
WO2003014064A1 (en) * 2001-07-31 2003-02-20 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
WO2003070247A1 (en) * 2002-02-20 2003-08-28 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
WO2003097586A1 (en) * 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor

Also Published As

Publication number Publication date
TWI394569B (zh) 2013-05-01
JP2007500753A (ja) 2007-01-18
KR101150324B1 (ko) 2012-06-13
NZ578264A (en) 2011-02-25
WO2004111009A1 (en) 2004-12-23
IL216046A0 (en) 2011-12-29
BRPI0411116A (pt) 2006-07-18
CY1108713T1 (el) 2014-04-09
TW201038269A (en) 2010-11-01
ATE411982T1 (de) 2008-11-15
IL215997A0 (en) 2011-12-29
DK2017265T3 (da) 2011-09-19
AU2010257277B2 (en) 2011-08-18
AU2010257277A1 (en) 2011-01-13
AU2004247721A1 (en) 2004-12-23
NZ590234A (en) 2012-07-27
KR20060058769A (ko) 2006-05-30
CA2756058A1 (en) 2004-12-23
SI2017265T1 (sl) 2011-09-30
NZ543713A (en) 2009-08-28
TW200509926A (en) 2005-03-16
SI1658269T1 (sl) 2009-04-30
HK1093727A1 (en) 2007-03-09
AU2004247721C1 (en) 2011-12-22
MXPA05013550A (es) 2006-04-05
DK1658269T3 (da) 2009-01-12
IL207335A (en) 2012-02-29
EP2017265B1 (en) 2011-05-25
KR101138216B1 (ko) 2012-09-05
IL207335A0 (en) 2010-12-30
CN102617464A (zh) 2012-08-01
CA2526872A1 (en) 2004-12-23
AU2004247721B2 (en) 2011-01-20
CY1111945T1 (el) 2015-11-04
JP2011153148A (ja) 2011-08-11
PL1658269T3 (pl) 2009-08-31
EP1658269B1 (en) 2008-10-22
EP2017265A1 (en) 2009-01-21
IL172457A0 (en) 2006-04-10
CA2526872C (en) 2013-02-05
PT2017265E (pt) 2011-07-29
HK1126488A1 (en) 2009-09-04
ES2318308T3 (es) 2009-05-01
DE602004017329D1 (de) 2008-12-04
TWI366461B (en) 2012-06-21
EP1658269A1 (en) 2006-05-24
JP4857113B2 (ja) 2012-01-18
TW201300361A (zh) 2013-01-01
ATE510824T1 (de) 2011-06-15
PT1658269E (pt) 2009-01-09
PL2017265T3 (pl) 2011-11-30
KR20110089464A (ko) 2011-08-08

Similar Documents

Publication Publication Date Title
AU2010257277B2 (en) Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US8071762B2 (en) Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7074805B2 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
JP5207983B2 (ja) 肥満および他のcns障害を治療するためのピラゾール類
US7375126B2 (en) Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
AU2011244937A1 (en) Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
HK1129383A (en) Fused compounds that inhibit vanilloid receptor subtype1(vr1) receptor
HK1126488B (en) Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
HK1093727B (en) Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees